Jacob Plieth· @JacobPlieth · X·· 2 天前评分90
正文 · 机器翻译
我预计今天会有多家卖方分析师围着 $MRNA 疲于应对，但 Evercore ISI 的 Cory Kasimov 提出了一个非常审慎的看法。很高兴看到！#Esmo26
5056 浏览 · 9 赞 · 0 转发 · 2 回复
会议摘要
Impact of BRAF V600K mutation in patients with resectable stage III melanoma: A subgroup analysis of the NADINA trial
https://esmocongress.esmo.org帖内回复
- BadInvestor9@badinvestor99
@JacobPlieth @A_May_MD What does he know? It’s a cure for all cancers. You just don’t see it yet.
- Jacob Plieth@JacobPlieth
Cory Casimov citing KOL re $MRNA: Patient mix matters; Neoadjuvant comps matter - cited Nadina & SWOG S1801 cc @A_May_MD; Uncertainty around OS (could change with mature data); Approval ≠ universal uptake. #Esmo26
来源：Jacob Plieth · x.com